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Mutations in DNA MMR genes, mainly MSH2 and
MLH1, are the most frequent cause of HNPCC, an auto-
somal dominant predisposition to colorectal cancer and
other malignancies. In our study we tested 46 unrelated
patients with suspected HNPCC, who met Bethesda cri-
teria. Tumors from probands (when available) were
tested by immunohistochemistry for deficiencies in
MLH1, PMS2, MSH2 and MSH6. DNA samples were
analyzed using high-resolution melting (HRM). PCR
amplicons were designed to scan complete MLH1,
MSH2 and MSH6 coding sequences using HRM method.
In the first stage of screening HRM analysis was per-
formed by scanning 14 amplicons selected as potentially
harboring most frequent mutations in Polish population
(Kurzawski et al., 2005). Sequencing was used to confirm
and characterize affected exons identified in HRM.
Three novel deleterious mutations were found in
MSH2 gene, one of them being splice acceptor site muta-
tion in exon 5, and two of them being nonsense muta-
tions in exons 6 and 8. Tumours from patients bearing
these mutations were lacking MSH2 protein. We found
also missense mutation in exon 8 of MLH1, which has
not been previously reported in Polish population.
Tumour from this patient exhibited weak expression of
MLH1 and PMS2 proteins. In 42 patients, only unspeci-
fied variants and polymorphisms have been found so far
(analysis is still in progress).
In our opinion, HRM is a rapid, inexpensive and high-
throughput method to prescreen for point mutation and
small deletions in MMR genes. Technical aspects concern-
ing analysis of one-replicate versus 2-replicates data will be
discussed. It must be noted that HRM cannot be used
alone, MLPA and array-CGH are still required for detec-
tion of large deletions and chromosome rearrangements.
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